146 related articles for article (PubMed ID: 26307390)
1. Cabergoline for Cushing's disease: A case report.
Pascual-Corrales E; Tomás Velázquez A; Zubieta JL; Salvador J; Galofré JC
Endocrinol Nutr; 2015 Dec; 62(10):516-8. PubMed ID: 26307390
[No Abstract] [Full Text] [Related]
2. Effect of cabergoline treatment on Cushing's disease caused by aberrant adrenocorticotropin-secreting macroadenoma.
Miyoshi T; Otsuka F; Takeda M; Inagaki K; Suzuki J; Ogura T; Date I; Hashimoto K; Makino H
J Endocrinol Invest; 2004 Dec; 27(11):1055-9. PubMed ID: 15754738
[TBL] [Abstract][Full Text] [Related]
3. Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease.
Feelders RA; de Bruin C; Pereira AM; Romijn JA; Netea-Maier RT; Hermus AR; Zelissen PM; van Heerebeek R; de Jong FH; van der Lely AJ; de Herder WW; Hofland LJ; Lamberts SW
N Engl J Med; 2010 May; 362(19):1846-8. PubMed ID: 20463350
[No Abstract] [Full Text] [Related]
4. Concomitant Cushing's Disease and Marked Hyperprolactinemia: Response to a Dopamine Receptor Agonist.
Shiraishi J; Koyama H; Shirakawa M; Ishikura R; Okazaki H; Kurajoh M; Shoji T; Moriwaki Y; Yamamoto T; Namba M
Intern Med; 2016; 55(8):935-41. PubMed ID: 27086808
[TBL] [Abstract][Full Text] [Related]
5. The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery.
Pivonello R; De Martino MC; Cappabianca P; De Leo M; Faggiano A; Lombardi G; Hofland LJ; Lamberts SW; Colao A
J Clin Endocrinol Metab; 2009 Jan; 94(1):223-30. PubMed ID: 18957500
[TBL] [Abstract][Full Text] [Related]
6. [Use of cabergoline in persisting Cushing's disease].
Illouz F; Dubois-Ginouves S; Laboureau S; Rohmer V; Rodien P
Ann Endocrinol (Paris); 2006 Sep; 67(4):353-6. PubMed ID: 17072242
[TBL] [Abstract][Full Text] [Related]
7. Limited value of cabergoline in Cushing's disease: a prospective study of a 6-week treatment in 20 patients.
Burman P; Edén-Engström B; Ekman B; Karlsson FA; Schwarcz E; Wahlberg J
Eur J Endocrinol; 2016 Jan; 174(1):17-24. PubMed ID: 26582653
[TBL] [Abstract][Full Text] [Related]
8. Remission with cabergoline in adolescent boys with Cushing's disease.
Güven A; Baltacıoğlu F; Dursun F; Cebeci AN; Kırmızıbekmez H
J Clin Res Pediatr Endocrinol; 2013 Sep; 5(3):194-8. PubMed ID: 24072089
[TBL] [Abstract][Full Text] [Related]
9. Pituitary-targeted medical therapy of Cushing's disease.
Alexandraki KI; Grossman AB
Expert Opin Investig Drugs; 2008 May; 17(5):669-77. PubMed ID: 18447593
[TBL] [Abstract][Full Text] [Related]
10. An Overlooked Cause of Hypokalemia.
Seow CJ; Young WF
Am J Med; 2017 Oct; 130(10):e433-e435. PubMed ID: 28687268
[No Abstract] [Full Text] [Related]
11. Cushing's disease in dogs: cabergoline treatment.
Castillo VA; Gómez NV; Lalia JC; Cabrera Blatter MF; García JD
Res Vet Sci; 2008 Aug; 85(1):26-34. PubMed ID: 17910968
[TBL] [Abstract][Full Text] [Related]
12. A 53-year-old woman with Cushing's disease and a pituitary tumor.
Barresi V; Lionti S; Messina E; Esposito F; Angileri FF; Cannavò S
Neuropathology; 2017 Feb; 37(1):86-90. PubMed ID: 27297703
[No Abstract] [Full Text] [Related]
13. Complete remission of Nelson's syndrome after 1-year treatment with cabergoline.
Pivonello R; Faggiano A; Di Salle F; Filippella M; Lombardi G; Colao A
J Endocrinol Invest; 1999 Dec; 22(11):860-5. PubMed ID: 10710275
[TBL] [Abstract][Full Text] [Related]
14. The Role of Dopamine Agonists in Pituitary Adenomas.
Giraldi EA; Ioachimescu AG
Endocrinol Metab Clin North Am; 2020 Sep; 49(3):453-474. PubMed ID: 32741482
[TBL] [Abstract][Full Text] [Related]
15. Nelson's syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment.
Casulari LA; Naves LA; Mello PA; Pereira Neto A; Papadia C
Horm Res; 2004; 62(6):300-5. PubMed ID: 15557761
[TBL] [Abstract][Full Text] [Related]
16. Cabergoline treatment for recurrent Cushing's disease during pregnancy.
Nakhleh A; Saiegh L; Reut M; Ahmad MS; Pearl IW; Shechner C
Hormones (Athens); 2016 Jul; 15(3):453-458. PubMed ID: 27394707
[TBL] [Abstract][Full Text] [Related]
17. Macroprolactinoma associated with Cushing's disease, successfully treated with cabergoline.
T'Sjoen G; Defeyter I; Van De Saffele J; Rubens R; Vandeweghe M
J Endocrinol Invest; 2002 Feb; 25(2):172-5. PubMed ID: 11929090
[TBL] [Abstract][Full Text] [Related]
18. The hypercoagulable state in Cushing's disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy.
van der Pas R; de Bruin C; Leebeek FW; de Maat MP; Rijken DC; Pereira AM; Romijn JA; Netea-Maier RT; Hermus AR; Zelissen PM; de Jong FH; van der Lely AJ; de Herder WW; Lamberts SW; Hofland LJ; Feelders RA
J Clin Endocrinol Metab; 2012 Apr; 97(4):1303-10. PubMed ID: 22278425
[TBL] [Abstract][Full Text] [Related]
19. Dopamine agonist-responsive Cushing's disease.
Anand G; Bink A; Beuschlein F; Schmid C
BMJ Case Rep; 2019 Feb; 12(2):. PubMed ID: 30765454
[TBL] [Abstract][Full Text] [Related]
20. Case report: Complete restoration of the HPA axis function in Cushing's disease with drug treatment.
Nguyen JT; Ferrière A; Tabarin A
Front Endocrinol (Lausanne); 2024; 15():1337741. PubMed ID: 38390203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
